Impact of hepatitis C virus eradication with direct-acting antivirals on glycidic metabolism

Abstract

Objective: To compare the glucose metabolism of patients with chronic hepatitis C virus infection treated with direct-acting antivirals (DAAs) in pretreatment and sustained viral response (SVR) periods. Materials and methods: This was an intervention pre-post study of 273 patients with chronic hepatitis C virus infection treated with DAAs from March 2018 to December 2019. Glycidic metabolism was evaluated through homeostasis model assessment (HOMA) -insulin resistance (IR) and HOMA-β indices and assessments of insulinemia and HbA1c levels. These parameters were analyzed with a T test by paired comparison of the means of the variables and Wilcoxon's test paired for the median; in the variables with an abnormal distribution, the Z score was generated for the mean in both the pretreatment and SVR periods. Statistical significance was considered at p ≤ 0.05. Results: Among 273 participants, 125 (45.8%) had prediabetes, and 50 (18.3%) had diabetes. In SVR, there was a significant increase in platelets, albumin, alkaline phosphatase, cholesterol and triglycerides and a significant decrease in aspartate aminotransferase, alanine aminotransferase, gamma GT and bilirubin. The HOMA-IR and HOMA-β indices increased in SVR from 1.95 to 2.29 (p = 0.087) and 71.20 to 82.60 (p = 0.001), respectively. Insulinemia increased from 7.60 μU/mL to 8.90 μU/mL (p = 0.011). HbA1c decreased from 5.6 to 5.4 (p < 0.001). Among patients with prediabetes and those with diabetes, the reduction in HbA1c values was significant (p = 0.006 and p = 0.026, respectively). Conclusion: SVR significantly impacts and leads to improvement in glucose metabolism in patients with chronic liver disease induced by hepatitis C virus.

Effect of Antiviral Drug on Viral Load Patients Infected with Hepatitis C Virus Genotype 3

“…The study ensured a balanced gender representation, with a predominance of females (69.23%), enriching the generalizability of the findings and facilitating gender-specific analyses. Age distribution showed a concentration in the middle-aged demographic (35-50 years), which constituted 38.4% of the participants, while younger (20-35 years) and older adults (50-65 years) were also well-represented, indicating the study's broad applicability across age groups (16)(17)(18). The methodology employed for ELISA Antibody Detection, PCR Confirmation, and Genotyping was robust, enabling a detailed examination of the participant cohort.…”

Hepatitis C virus eradication in people living with human immunodeficiency virus: Where are we now?

“…Morales et al [ 38 ] conducted a retrospective analysis of HCV-positive patients with altered HbA1c levels treated with SOF regimens from January 2014 to March 2015 and demonstrated a significant reduction ( P < 0.005) in HbA1c after HCV eradication. Sparvoli et al [ 39 ] compared glucose metabolism by HOMA among 273 HCV patients treated with DAAs from March 2018 to December 2019 and reported a significant reduction in HbA1c among prediabetic patients ( P = 0.006).…”